Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
FL 0.405 −1.2% SSRM 35.29 −2.9% CD 0.230 +0.0% GEN 0.070 +0.0% ALS 55.11 −4.1% WGX 4.23 −4.5% LIFT 3.06 −2.9% NTR 94.63 +0.4% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0% RJX 0.030 +0.0% PRU 4.54 −2.2% MOO 0.720 +0.0% BSX 0.810 −14.7% SLI 2.96 −3.9% FL 0.405 −1.2% SSRM 35.29 −2.9% CD 0.230 +0.0% GEN 0.070 +0.0% ALS 55.11 −4.1% WGX 4.23 −4.5% LIFT 3.06 −2.9% NTR 94.63 +0.4% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0% RJX 0.030 +0.0% PRU 4.54 −2.2% MOO 0.720 +0.0% BSX 0.810 −14.7% SLI 2.96 −3.9%
Other

Light AI Version 1.0 Software Completion

By The Northwire Desk — AI Analysis Nov 18, 2025 · 07:00 ALGO · 0.285 LIGHT AI INC.
ALGO · Price

Executive Summary

  • Light AI Inc. announced the completion of Version 1.0 of its AI‑powered diagnostic software platform, moving from R&D to commercialization.
  • The app analyzes smartphone images to detect Group A Streptococcus (Strep A) on iOS and Android devices, delivering rapid results without swabs or lab tests.
  • A pilot study with a major global healthcare provider is planned to validate performance in urgent‑care settings and pave the way for broader commercial rollout.

Key Details

  • Software Release: Version 1.0 of Light AI’s commercial platform now available; compatible with Apple iOS and Android smartphones.
  • Diagnostic Focus: Initial indication – detection of Group A Streptococcus (Strep A) from smartphone images; future expansion to eye, skin conditions and other diagnostics.
  • Performance Claims (pre‑FDA validation): 96.57% overall accuracy; Negative Predictive Value of 100% for distinguishing viral vs. bacterial pharyngitis.
  • Commercialization Path: Transition from development to commercialization announced; next step is a pilot study with a major global healthcare provider in urgent‑care settings.
  • Strategic Vision: Build a cloud‑based “Digital Clinical Lab” that turns smartphones into diagnostic tools, reducing reliance on traditional lab infrastructure.
  • CEO Quote: “This milestone marks our transition from development to commercialization… helping reduce unnecessary physician visits, lower testing costs, and curb antibiotic overuse.” – Peter Whitehead, CEO.
  • CFO Contact: George Reznik – Telephone: 604‑307‑6800; Email: [email protected]

Notable Quotes

“This milestone marks our transition from development to commercialization,” said Peter Whitehead, CEO of Light AI. “Our technology is built to provide real‑time diagnostic insights, helping reduce unnecessary physician visits, lower testing costs, and curb antibiotic overuse.”

Read the original news release →

More from LIGHT AI INC.

Jun 29, 2026 · 07:00

Pre-revenue AI diagnostics developer advances regulatory clearance for smartphone-based Strep A detection amid persistent cash burn and dilution risk.

Production / Operations Jun 22, 2026 · 18:41

Pre-revenue AI diagnostics company closes dilutive financing to fund regulatory milestones amid going concern risks.

Financings Jun 19, 2026 · 18:00

Light AI Announces Closing of C$5,000,000 Secured Convertible Debenture Unit Financing

Financings Jun 15, 2026 · 18:25

Light AI pilots Strep A diagnostic in NZ as FDA pivotal trial launches, but pre-revenue status and going concern risk persist.

Production / Operations Jun 04, 2026 · 07:00

Light AI Advances FDA Pivotal Trial for Strep A AI Diagnostic Amid Cash Burn and Dilutive Financing

Regulatory May 21, 2026 · 07:15

Light AI’s C$5 Million Lifeline Comes With Dilutive Terms and Board Strings as Cash Burn Intensifies

Financings